Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

07 mai 2026 13h54 HE | Source: Direct Meds

Direct Meds GLP-1 Weight Loss Program Evaluated: LegitScript-Certified Compounded Semaglutide and Sublingual Access for Cash-Pay Patients in 2026

WILMINGTON, DE, May 07, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: This article is for informational and educational purposes only and does not constitute medical advice. GLP-1 medications require...
07 mai 2026 11h37 HE | Source: Bay Clinic of Chiropractic

Bay Clinic of Chiropractic Expands Functional Medicine Program to Address Complex Chronic Conditions

Panama City, FL, May 07, 2026 (GLOBE NEWSWIRE) -- Panama City, FL - May 07, 2026 - - Bay Clinic of Chiropractic in Panama City, FL, has expanded its integrated functional medicine program to...
05 mai 2026 08h00 HE | Source: Spyre Therapeutics, Inc.

Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Announced positive topline induction data from Part A of the Phase 2 SKYLINE trial of SPY001, demonstrating best-in-class efficacy potential and a safety profile consistent with the α4β7 class ...
04 mai 2026 13h00 HE | Source: DelveInsight Business Research LLP

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight

New York, USA, May 04, 2026 (GLOBE NEWSWIRE) -- Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsight The...
01 mai 2026 06h50 HE | Source: Research and Markets

Adalimumab, Infliximab and Etanercept Biosimilars Trastuzumab Biosimilars Research Report 2026: $8.05 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2035

Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2026" has been added to ResearchAndMarkets.com's offering. The adalimumab,...
29 avr. 2026 20h55 HE | Source: Mesoblast Limited

Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million

Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) --...
29 avr. 2026 07h22 HE | Source: SNS Insider pvt ltd

Biologics Market Size is Poised to be USD 1,283.29 Billion by 2035; Growth is Propelling as it is an Essential Modern Healthcare Globally | SNS Insider

Biologics market grows strongly, driven by chronic diseases, innovation in gene therapies, and rising demand for targeted, effective treatments globally.
14 avr. 2026 20h10 HE | Source: Mesoblast Limited

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired...
13 avr. 2026 07h00 HE | Source: Soleo Health Holdings, Inc.

Soleo Health Opens New Ambulatory Infusion Center in Louisville, Kentucky

FRISCO, Texas and LOUISVILLE, Ky., April 13, 2026 (GLOBE NEWSWIRE) -- Soleo Health, a national provider of complex specialty pharmacy services, announced today the opening of its new ambulatory...
10 avr. 2026 04h43 HE | Source: Research and Markets

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "Crohn's Disease: Eight-Market Drug Forecast and Market Analysis - Update (2025)" report has been added to ResearchAndMarkets.com's offering.This...

Page suivante